Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction

Chinese PLA General Hospital709 enrolled

Overview

GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.

Study Type

OBSERVATIONAL

Enrollment

709

Conditions

Coronary Angiography Glucagon-like Peptide-1

Interventions

plasma glucagon-like peptide-1 levelsDIAGNOSTIC_TEST

The plasma GLP-1 levels was determined by enzymatic assays.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * consecutive patients of acute AMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment. Exclusion Criteria: * patients with cancer, and patients who were taking a DPP4 inhibitor or a glucagon-like peptide-1 (GLP-1) analogue